The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management

Alexandra G. Lopez-Aguiar, MD, MS[a], Cecilia G. Ethun, MD, MS[a], Mohammad Y. Zaidi, MD, MS[a], Flavio G. Rocha, MD[b], George A. Poultsides, MD[c], Mary Dillhoff, MD[d], Ryan C. Fields, MD[e], Kamran Idrees, MD[f], Clifford S. Cho, MD[g], Daniel E. Abbott, MD[h], Kenneth Cardona, MD[a], Shishir K. Maithel, MD[a,*]

[a] Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA
[b] Department of Surgery, Virginia Mason Medical Center, Seattle, WA
[c] Department of Surgery, Stanford University Medical Center, Stanford, CA
[d] Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
[e] Department of Surgery, Washington University School of Medicine, St. Louis, MO
[f] Division of Surgical Oncology, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN
[g] Division of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI
[h] Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI

A R T I C L E   I N F O

A B S T R A C T

Background: Management of <2-cm pancreatic neuroendocrine tumors is controversial. Although often indolent, the oncologic heterogeneity of these tumors particularly related to lymph node metastases poses challenges when deciding between resection versus surveillance.

Methods: We analyzed all patients who underwent resection of primary nonfunctional <2-cm with curative-intent at 8 institutions of the US Neuroendocrine Tumor Study Group from 2000 to 2016. Pancreatic neuroendocrine tumors with poor differentiation and Ki-67 > 20% were excluded. Our primary aim was to create a lymph node risk score that predicted lymph node metastases accurately for <2-cm pancreatic neuroendocrine tumors, utilizing readily available preoperative data.

Results: Of 695 patients with resected pancreatic neuroendocrine tumors, 309 were <2 cm. Of these small pancreatic neuroendocrine tumors, 25% were proximal (head/uncinate), 23% had a Ki-67 > 3%, and only 8% were moderately differentiated. Also, *only* 9% of all <2-cm pancreatic neuroendocrine tumors were lymph node (+). Indeed lymph node positivity was associated with worse 5-year recurrence-free survival compared with lymph node (−) disease (80% vs 96%; $P = .007$). Factors known preoperatively to be associated with lymph node metastases were proximal location (odds ratio 4.0; $P = .002$) and Ki-67 $\geq$3% (odds ratio 2.7; $P = .05$). Moderate differentiation was not associated with lymph node (+) disease. Location and Ki-67 were assigned a value weighted by their odds ratio: (distal= 1, proximal= 4, and Ki-67 < 3% = 1 and Ki-67 $\geq$ 3% = 3), which formed a lymph node risk score ranging 1–7. Scores were categorized into low (1–2), intermediate (3–4), and high (5–7) risk groups. Incidence of lymph node metastases increased progressively based on risk group, with low = 3.2%, intermediate = 13.8%, and high = 20.5%. Only 3.4% of pancreatic neuroendocrine tumors with a Ki-67 < 3% in the distal pancreas were lymph node (+) compared with 21.4% of pancreatic neuroendocrine tumors with a Ki-67 $\geq$ 3% in the head/uncinate.

Conclusion: This simple and novel lymph node risk score utilizes readily available preoperative factors (tumor location and Ki-67) to stratify risk of lymph node metastases accurately s for < 2-cm pancreatic neuroendocrine tumors and may help guide management strategy.

© 2019 Elsevier Inc. All rights reserved.

E-mail address: smaithe@emory.edu (S.K. Maithel).

Introduction

Pancreatic neuroendocrine tumors (PanNETs) are a rare and heterogeneous tumor type that currently represent about 3% of all pancreatic malignancies.[1] Although PanNETs are relatively indolent neoplasms, 5-year survival can be as great as 90%−100% and as low as 25%.[2] Nearly 20% of PanNETs are considered to be "functional" tumors, manifesting with clinical signs and symptoms secondary to hormonal activation.[1,3] The large majority of PanNETs, however, are classified as "nonfunctional," and thus either present late in their disease course attributable to tumor burden or are identified by chance.[2,3] As cross-sectional imaging increases in frequency and quality, nonfunctional PanNETs are being diagnosed at an increasingly small size.[4,5] The behavioral heterogeneity that distinguishes PanNETs has been noted even among PanNETs <2 cm, with multiple studies reporting instances of nodal metastasis, distant metastasis, and disease recurrence among this group.[5−9] As a result, standardizing management, follow-up surveillance, and prognosis for these tumors remains a challenge.[10]

The seven-fold increase in the incidence of small PanNETs in the United States during the past 2 decades, as well as the uncertainty of their malignant potential, has created controversy about the optimal management of these neoplasms.[11,12] Although operative resection remains the only cure for PanNETs,[10] several studies have proposed observation for tumors <2 cm as the preferred management strategy.[11−14] However, guidelines remain unclear, because both the European Neuroendocrine Tumor Society (ENETS) and the National Comprehensive Cancer Network offer several viable treatment strategies, including both resection and observation.[15,16] Without a definitive consensus, health care teams must utilize known prognostic factors to predict tumor behavior and to help choose the appropriate approach for each individual patient.

Although a number of poor prognostic factors have been implicated in the natural history of PanNETs, the impact of lymph node metastases on survival in nonfunctional PanNETs has been demonstrated clearly.[17−23] According to the American Joint Committee on Cancer, nodal disease automatically renders a stage III diagnosis of stage III disease in neuroendocrine tumors.[24] As such, even in the indolent group of <2-cm PanNETs, lymph node metastases may serve as a surrogate for aggressive tumor biology, which can aid in the decision to resect or observe these neoplasms.

Given that only an average of 40% of all nonfunctional PanNETs have lymph node metastases, an accurate preoperative method for staging nodal status may be used to inform the surgical plan.[17] The aim of this study was to create a lymph node risk score (LNRS) that accurately predicts lymph node metastases accurately for <2-cm nonfunctional PanNETs, utilizing readily available preoperative data.

Methods

Study population

The US Neuroendocrine Tumor Study Group (US-NETSG) is a collaboration of 8, high-volume institutions from across the United States, including Emory University (Atlanta, GA), University of Michigan (Ann Arbor, MI), The Ohio State University (Columbus, OH), Stanford University (Stanford, CA), Vanderbilt University (Nashville, TN), Virginia Mason Clinic (Seattle, WA), Washington University (St. Louis, MO) and University of Wisconsin (Madison, WI). This database is composed of all patients from these institutions with neuroendocrine tumors of the abdomen, specifically those located in the stomach, duodenum, ampulla, pancreas, liver, gallbladder, small bowel, appendix, colon, rectum, spleen, and peritoneum, who underwent operative resection from January 1,

2000, to December 31, 2016. For the purpose of this study, we included only patients with <2-cm, nonfunctional primary PanNETs who underwent curative-intent resection. Poorly differentiated and metastatic PanNETs, as well as those with a Ki-67 > 20% were excluded. All 30-day mortalities and R2 resections were also excluded. The primary end point was the presence of lymph node metastases, with the aim to create a preoperative LNRS to predict accurately the presence of nodal metastases for <2-cm PanNETs.

Study variables

Pertinent baseline demographic, preoperative, intraoperative, pathologic, and postoperative data were collected retrospectively through review of the medical records. Comorbidities were defined using the American College of Surgeons National Surgical Quality Improvement Program risk calculator. Cancer staging was assigned per the guidelines of the American Joint Committee on Cancer 7th edition.[25] Neoadjuvant and adjuvant therapy, disease recurrence, and survival data were also collected. Approval by the institutional review board was obtained at each institution before any data retrieval, and survival information was verified with the Social Security Death Index when appropriate.

Statistical analyses

All statistical tests were executed using SPSS v 23.0 (IBM, Inc, Armonk, NY), with statistical significance predefined as $P < .05$. Descriptive and comparative analyses were performed for the entire cohort. A χ^2 analysis and Fisher exact tests were used to compare categorical variables, and Student t test was used for continues variables, where indicated. Kaplan-Meier log-rank plots were calculated for recurrence-free survival (RFS), and univariable logistic regression was performed to evaluate both the clinicopathologic variables associated with lymph node positivity and the preoperative LNRS generated subsequently.

Results

Patient variables

Of 2,182 patients with neuroendocrine tumors listed in the US-NETSG database, 695 patients had low-to-intermediate, nonfunctional PanNETs. They underwent resection with a curative intent, 309 of which were <2 cm in size. Baseline demographics and clinicopathologic features of this study cohort are summarized in Table I. Mean age was 58 years, 48% were male ($n = 147$), and 76% ($n = 231$) were Caucasian. Mean tumor size was 1.3 cm, and, given that 75% ($n = 232$) of tumors were located distally in the neck, body, or tail of the pancreas, only 25% ($n = 77$) were located proximally in the head or uncinate. With regard to pathologic data, 93% ($n = 258$) of tumors were well differentiated, 77% ($n = 177$) had a Ki-67 index <3%, and 9% ($n = 22$) were lymph node positive.

RFS analysis

Median follow-up was 35 months (interquartile range 13.9−59.1), and 13 patients (4%) experienced recurrence of disease after resection. Of those patients who developed a recurrence, 6 recurred locoregionally and 7 recurred distantly (1 in bone, 4 in liver, and 2 in lung). On Kaplan-Meier analysis, the 5-year RFS for patients with lymph node−positive disease was 80% compared with 96% for those with lymph node−negative disease ($P = .007$; Figure). On univariable Cox regression, there was a 6-fold increase in risk of recurrence among patients with lymph node−positive disease versus lymph node−negative disease (hazard ratio 5.9,

Table I
Baseline demographics and clinicopathologic variables of patients with <2-cm low/intermediate grade, nonfunctional PanNETS[*]

Baseline variables	n (%)
Age (y), mean $\pm$ SD	58 $\pm$ 12
Male, n (%)	147 (48)
BMI, mean $\pm$ SD	29 $\pm$ 6
Comorbidities, n (%)[†]	
0	106 (34)
1	91 (29)
$\geq$2	108 (35)
Race, n (%)	
White	231 (76)
Black	32 (11)
Other	40 (13)
ASA class, n (%)	
1	6 (2)
2	143 (47)
3	151 (50)
4	3 (1)
CgA (ng/L), mean $\pm$ SD	176 $\pm$ 332

Operative/pathologic data	n (%)
Tumor size (cm), mean $\pm$ SD	1.3 $\pm$ 0.4
Location of tumor in pancreas, n (%)	
Head/uncinate (proximal)	77 (25)
Neck/body/tail (distal)	232 (75)
Surgical technique, n (%)	
Open	198 (64)
Laparoscopic	70 (23)
Other	31 (13)
Type of resection, n (%)	
Enucleation	28 (9)
Classic pancreatoduodenectomy	25 (8)
Pylorus preserving pancreatoduodenectomy	36 (12)
Central pancreatectomy	22 (7)
Distal pancreatectomy	195 (63)
Total pancreatectomy	3 (1)
Tumor differentiation, n (%)	
Well	258 (93)
Moderate	21 (8)
Ki-67 index, n (%)	
<3%	177 (77)
3%−20%	52 (23)
Lymph node-positive, n (%)	22 (9)
Lymph node yield, median (IQR)	8 (3−13)
Pancreatoduodenectomy	11 (7−17)
Distal pancreatectomy	8 (4−12)
Enucleation/central pancreatectomy	1 (1−2)

Postoperative data	n (%)
Clavien-Dindo classification, n (%)[‡]	
I	48 (26)
II	67 (37)
IIIa	43 (23)
IIIb	11 (6)
IVa	11 (6)
IVb	3 (2)
Disease recurrence	13 (4)
Region of recurrence	
Locoregional	6 (46)
Locoregional + distant	0 (0)
Distant	7 (54)

(continued on next column)

Table I (continued)

Postoperative data	n (%)
Deaths	11 (4)
Time to death	
<30 days	0 (0)
31−60 days	0 (0)
61−90 days	0 (0)
>90 days	11 (100)

Lymph node yield solely refers to the median number of lymph nodes removed in the specific operations listed (pancreatoduodenectomy, etc). This does not specifically represent patients with lymph-node positive disease, but rather any patient in the cohort who underwent that particular surgery.

PanNETS, pancreatic neuroendocrine tumors; SD, standard deviation; BMI, body mass index; ASA, American Society of Anesthesiologists; CgA, chromogranin A; IQR, interquartile range.

[*] From the US-NETSG database regarding patients who underwent curative-intent resection from 2000−2016 (n = 309).

[†] Comorbidities are defined as any concurrent medical condition, including, but not limited to, heart disease, chronic pulmonary disease, diabetes, renal disease, and liver disease as per the American College of Surgeons National Surgical Quality Improvement Program Risk Calculator.

[‡] Clavien-Dindo is a grading scale for ranking the severity of postoperative complications ranging from I to V, where I represents the lowest acuity complication (not requiring pharmacologic treatment or surgical, endoscopic, or radiologic intervention), and V represents death.

located proximally in the pancreas (55% vs 23%; $P = .003$), to have an advanced T stage of T3/T4 (18% vs 3%; $P = .006$), lymphovascular invasion (61% vs 8%; $P < .001$), and perineural invasion (39% vs 12%; $P = .005$; Table II). On binary logistic regression, proximal tumor location (odds ratio [OR] 4.0, 95% CI 1.6−9.7; $P = .002$), Ki-67> 3% (OR 2.7, 95% CI 1.0−7.2; $P = .054$), positive margins (OR 3.3, 95% CI 1.0−11.0; $P = .052$), lymphovascular invasion (OR 17.2, 95% CI 5.9−50.1; $P < .001$), perineural invasion (OR 4.9, 95% CI 1.7−14.0; $P = .003$), and advanced T stage (OR 8.6, 95% CI 2.2−33.1; $P = .002$) were all associated with an increased risk for lymph node positivity (Table III). When assessing lymph node positivity simply by tumor location, 10 of the 193 (5.2%) distal tumors had lymph node 4 positive disease compared with 12 of 67 (17.9%) proximal tumors ($P < .01$).

The LNRS was created by assigning a value for the risk score OR on logistic regression for the preoperatively available factors of tumor location and Ki-67 index. For proximal tumor location, the OR was 4. Thus, a score of 1 was given for distal tumor location and a score of 4 for proximal tumor location. For the Ki-67 index $\geq$3%, the OR was 2.7, so a score of 1 was given for a Ki-67 <3% and a score of 3 for a Ki-67 $\geq$3%. The final risk score ranged 1−7, depending on the presence of one or both preoperative factors. The scores were then restratified into 3 groups, where a score of 1−2 corresponded with "low risk," a score of 3−4 corresponded with "intermediate risk," and a score of 5−7 corresponded with "high risk" for lymph node positivity. A total of 63% ($n = 195$) of the cohort was classified as having a low LNRS, a total of 20% ($n = 61$) as having an intermediate LNRS, and a total of 17% ($n = 53$) as having a high LNRS. The incidence of lymph node positivity ranged from 3% to 14% to 21% for a low, intermediate, and high LNRS, respectively (Table IV). Using binary logistic regression, an intermediate LNRS corresponded with a nearly 5-fold increase in risk for positive lymph nodes compared with a low LNRS (OR 4.9, 95% CI 1.5−15.7; $P = .007$), and a high LNRS was associated with an almost 8-fold increase in risk for lymph node positivity (OR 7.9, 95% CI 2.5−24.9; $P < .001$; Table IV). For patients with both a distally located tumor and a Ki-67 <3%, lymph node metastases occurred at a rate of 3%. Conversely, 21% of patients with tumors having both a proximal location and a Ki-67 $\geq$3% had node positive disease.

95% confidence interval [CI] 1.4−25.3; $P = .016$). Other pathologic factors, including final margin status, lymphovascular invasion, perineural invasion, tumor grade, and T stage, were not associated with RFS in this cohort.

Lymph node positivity and the LNRS

Lymph node−positive patients when compared with those with lymph node−negative disease were more likely to have tumors

Figure. Kaplan-Meier survival curve for recurrence-free survival in lymph node–positive versus lymph node–negative patients with <2 cm low/intermediate grade nonfunctional pancreatic neuroendocrine tumors.

Discussion

Small PanNETs are a heterogeneous group of neoplasms with controversy regarding their best management. This study showed an association between lymph node metastases and decreased RFS among <2-cm, nonfunctional PanNETs. The preoperatively available factors of tumor location and Ki-67 index were utilized to create a simple and novel LNRS to stratify accurately these small tumors for a risk of lymph node metastases. Indeed, using this LNRS ranging 1–7 based on the ORs on logistic regression for tumor location and Ki-67 index, <2-cm PanNETs were grouped into a low-risk group (score 1–2), an intermediate-risk group (score 3–4), and a high-risk group (score 5–7). The incidence of lymph node positivity increased with increases in the LNRS, from 3% to 14% to 21%, respectively. Compared with low-risk tumors, PanNETs classified as intermediate risk were 5 times more likely to be lymph node positive (OR 4.9; $P = .007$), and the high-risk PanNETs had a nearly 8-fold increase in lymph node metastases (OR 7.9; $P < .001$).

Although the diagnosis of small, nonfunctional PanNETs has increased in the past few decades, attributed in large part to the increase in cross-sectional imaging, current guidelines for the optimal management of these tumors remain ambiguous and inconsistent.[11] ENETS recommends either surveillance or resection for <2-cm PanNETs, with careful weighing of the risks and benefits on a case-by-case basis.[16] Likewise, National Comprehensive Cancer Network guidelines offer enucleation +/- regional lymphadenectomy, anatomic resection, and observation as viable management strategies.[15] Even the North American Neuroendocrine Tumor Society has an unclear consensus, suggesting enucleation or operative resection versus observation, depending on individual patient characteristics.[26] Findings in the literature have been conflicting as well. Although several studies, such as those of Lee et al[13] and Sadot et al,[11] have concluded that it is safe to manage <2-cm PanNETs by observation,[27] others, including Gratian et al[12] and Haynes et al,[9] have suggested that these small tumors may still display an aggressive course.[6,28] Of course, with advances in functional imaging modalities, such as DOTATATE, for example, the ability to preoperatively assess aggressive behavior via evaluation for lymph node metastasis may improve. In the current study, 9% ($n = 22$) of patients had lymph node metastases at resection, and 13 recurred within a median follow-up of 35 months. Of note, those patients with a high LNRS had a rate of lymph node metastases as great as 21%. These findings support the evidence that <2-cm PanNETs may

Table II
Distribution of pathologic factors among patients with < 2-cm low/intermediate grade, nonfunctional PanNETS[*]

Pathologic factors	Lymph node negative ($n = 287$)	Lymph node positive ($n = 22$)	P value[†]
Location of tumor in pancreas, n (%)			.003
Proximal	55 (23)	12 (55)	
Distal	183 (77)	10 (45)	
Tumor size			.677
<1 cm	57 (24)	4 (18)	
1−1.5 cm	114 (48)	10 (46)	
>1.5 cm	67 (28)	8 (36)	
AJCC T-stage, n (%)			.006
T1/T2	231 (97)	18 (82)	
T3/T4	6 (3)	4 (18)	
Tumor differentiation, n (%)			.646
Well	199 (92)	16 (89)	
Moderate	17 (8)	2 (11)	
Ki-67 Index, n (%)			.090
<3%	136 (77)	10 (56)	
3%−20%	41 (23)	8 (44)	
Mitotic rate (per 10 HPF), n (%)			.081
<2	141 (92)	9 (75)	
2−20	12 (8)	3 (25)	
Final resection status, n (%)			.065
R0[‡]	222 (94)	18 (82)	
R1[‡]	15 (6)	4 (18)	
Lymphovascular invasion, n (%)			< .001
Negative	186 (92)	7 (39)	
Positive	17 (8)	11 (61)	
Perineural invasion, n (%)			.005
Negative	161 (88)	11 (61)	
Positive	21 (12)	7 (39)	

PanNETS, pancreatic neuroendocrine tumors; *AJCC*, American Joint Committee on Cancer; *HPF*, high power fields.

[*] From the US-NETSG database regarding patients who underwent curative-intent resection from 2000 to 2016, stratified by lymph node positivity.

[†] Statistical significance is indicated by $P < .05$.

[‡] R0 resection refers to negative margins on pathologic review of the specimen, and R1 resection refers to positive margins on pathologic review of the specimen.

manifest aggressive behavior, thus highlighting the need for both optimizing and standardizing their management.

When considering the characteristics of PanNETs that may predict poor outcomes and inform the decision to resect versus observe, there is substantial evidence supporting lymph node metastases as a marker of worse disease.[17,18,21,22] A study by Partelli et al[17] demonstrated a 5-year disease-free survival of 70% for N1 disease versus 97% for N0 disease among patients with nonfunctional PanNETs. Similarly, the study by Postlewait et al[29] showed that the 5-year RFS was 40% for patients with nodal metastasis compared with 85% in patients with lymph node−negative disease. These findings are in accordance with the current study, because lymph node−positive patients in our cohort had a 5-year RFS of 80% compared with 96% for those who were lymph node negative. Not only has lymph node metastasis in PanNETs been shown to correlate with decreased survival, but PanNETs specifically <3 cm metastasize at a rate as great as 33%.[30] Given this high incidence, the ability to predict nodal metastasis preoperatively in small PanNETs is of paramount importance and clinical relevance.

A number of clinicopathologic factors are correlated with lymph node positivity in PanNETs, including tumor location in the head of the pancreas, increasing tumor size, lymphovascular invasion, and an increased Ki-67 index.[29,31,32] In the current study, although multiple factors were associated with an increased risk for lymph node metastasis, only tumor location and Ki-67 index were reliably available preoperatively. Hashim et al[31] showed that PanNETs located proximally in the pancreas had a 2.8 times increase in risk for nodal disease compared with those in the body/tail. In accordance with Hashim et al,[31] our study demonstrated that proximal tumors had a 4-fold increase in risk for nodal metastases and that a Ki-67 index ≥3% had a nearly 3-fold increase in risk for nodal

positivity. Because Ki-67 on preoperative biopsy has been found to correlate well with Ki-67 of the resected specimen and because it is more sensitive than other clinicopathologic factors at predicting malignant behavior of neuroendocrine neoplasms, Ki-67 appears to be able to serve as a useful preoperative prognostic indicator.[33−35] Thus, tumor location and Ki-67 were combined to create a reliable LNRS from which to predict accurately the risk for lymph node metastasis among patients with <2-cm PanNETs. Access to such information preoperatively may be used to guide and optimize patient management.

This study is limited by its retrospective design, which may involve incomplete preoperative, pathologic, and survival data for the entire cohort. Specific limitations include incomplete data on preoperative, radiographically measured tumor size, preoperative radiographically assessed lymph node status, and Ki-67 data based on the preoperative biopsy specimen. It is also limited by the small overall number of patients who ultimately had positive lymph nodes ($n = 22;9\%$) from which we based the LNRS; however this low rate of lymph node−positive disease is an inherent characteristic of this cohort of patient with small < 2-cm PanNETs. Furthermore, because only operatively resected neuroendocrine tumors were included in this database, those with worse tumor biology or worrisome features may have been selected. Nonetheless, this study is one of the largest cohorts of <2-cm PanNETs reported, and the use of 8 geographically diverse, academic institutions from across the United States. eliminates single-institution bias.

In conclusion, a simple LNRS utilizing the readily available preoperative factors of tumor location and Ki-67 can stratify accurately the risk of lymph node metastases for <2-cm PanNETs. This risk score may be used to guide future treatment strategies by informing the decision to resect versus observe patients with small,

Table III
Association of pathologic factors with risk for lymph node positivity in patients with < 2-cm low/intermediate grade, nonfunctional, PanNETS[*]

Pathologic factors	Logistic regression	
	Lymph node positivity	
	OR (95% CI)	P value[†]
Tumor location in pancreas		
Distal	**Ref**	—
proximal[‡]	**4.0 (1.6–9.7)**	**.002**
Tumor size		
<1 cm	Ref	—
1–1.5 cm	1.25 (0.4–4.2)	.716
>1.5 cm	1.7 (0.5–5.9)	.405
Tumor differentiation		
Well	Ref	—
Moderate	1.5 (0.3–6.9)	.631
Ki-67 index[‡]		
<3%	**Ref**	—
3%–20%	**2.7 (1.0–7.2)**	**.054**
Final resection status		
R0	Ref	—
R1	3.3 (1.0–11.0)	.052
Mitotic rate (per 10 HPF)		
<2	Ref	—
2–20	3.9 (0.9–16.4)	.062
Lymphovascular invasion		
Negative	Ref	—
Positive	17.2 (5.9–50.1)	<.001
Perineural invasion		
Negative	Ref	—
Positive	4.9 (1.7–14.0)	.003
Advanced T stage		
T1/T2	Ref	—
T3	8.6 (2.2–33.1)	.002

PanNETS, pancreatic neuroendocrine tumors; *OR*, odds ratio; *CI*, confidence interval; *HPF*, high power fields.

[*] From the US-NETSG database regarding patients who underwent curative-intent resection from 2000 to 2016.

[†] Statistical significance is indicated by P < .05.

[‡] Bold values indicate preoperatively measurable variables through imaging or biopsy.

Table IV
Rate and risk of lymph node positivity according to the preoperative lymph node risk score among patients with <2-cm, low/intermediate grade, nonfunctional PanNETS[*]

	Lymph node positivity[†]			
	Incidence (%)	P value[‡]	OR (95% CI)	P value[‡]
Lymph node risk score		<.001		
Low (score 1–2; n = 195)	3		Ref	—
Intermediate (score 3–4; n = 61)	14		4.9 (1.5–15.7)	.007
High (score 5–7; n = 53)	21		7.9 (2.5–24.9)	<.001

PanNETS, pancreatic neuroendocrine tumors; *OR*, odds ratio; *CI*, confidence interval.

[*] From the US-NETSG database regarding patients who underwent curative-intent resection from 2000 to 2016.

[†] A χ^2 analysis was used to compare incidence of lymph node positivity among the risk groups, while binary logistic regression was used to evaluate risk for nodal disease based on the assigned lymph node risk score.

[‡] Statistical significance is indicated by P < .05.

nonfunctional PanNETs. This study demonstrated a rate of lymph node metastasis as great as 21% in patients with a high-risk LNRS. Ultimately, this LNRS may provide useful information to inform a meaningful conversation in the preoperative setting to determine the optimal management strategy for patients with <2-cm PanNETs.

Conflict of interest

The authors have no conflicts of interest to disclose.

Funding

References

1. Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: An analysis of the AJCC and ENETS staging classifications. *Ann Surg*. 2012;256: 321–325.
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. *Gastroenterology*. 2008;135:1469–1492.
3. Shanahan MA, Salem A, Fisher A, et al. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. *J Surg Res*. 2016;201: 38–43.
4. Zerbi A, Falconi M, Rindi G, et al. Clinicopathological features of pancreatic endocrine tumors: A prospective multicenter study in Italy of 297 sporadic cases. *Am J Gastroenterol*. 2010;105:1421–1429.
5. Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: The Massachusetts General Hospital experience from 1977 to 2005. *Arch Surg*. 2007;142:347–354.
6. Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. *Ann Surg Oncol*. 2013;20:2815–2821.
7. Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. *Ann Surg Oncol*. 2010;17: 1621–1627.
8. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? *J Clin Oncol*. 2007;25:5609–5615.
9. Haynes AB, Deshpande V, Ingkakul T, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: Short-term and long-term patient outcomes. *Arch Surg*. 2011;146:534–538.
10. Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. *World J Gastroenterol*. 2015;21:9512–9525.
11. Sadot E, Reidy-Lagunes DL, Tang LH, et al. Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: A matched case-control study. *Ann Surg Oncol*. 2016;23:1361–1370.
12. Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. *Ann Surg Oncol*. 2014;21:3515–3521.
13. Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): Role for nonoperative management. *Surgery*. 2012;152:965–974.
14. Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. *Surgery*. 2011;150:75–82.
15. Clark OH, Benson 3rd AB, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine tumors. *J Natl Compr Canc Netw*. 2009;7:712–747.
16. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. *Neuroendocrinology*. 2016;103:153–171.
17. Partelli S, Gaujoux S, Boninsegna L, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). *JAMA Surg*. 2013;148:932–939.
18. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. *Ann Oncol*. 2008;19: 903–908.
19. Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help? *World J Surg*. 2000;24:1312–1318.
20. Sarmiento JM, Farnell MB, Que FG, Nagorney DM. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. *World J Surg*. 2002;26:1267–1271.
21. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. *J Clin Oncol*. 2002;20: 2633–2642.
22. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: Factors correlated with survival. *Ann Oncol*. 2005;16:1806–1810.

23. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. *Mod Pathol*. 2010;23:824–833.
24. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin*. 2017;67:93–99.
25. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010;17:1471–1474.
26. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. *Pancreas*. 2013;42: 557–577.
27. Regenet N, Carrere N, Boulanger G, et al. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study. *Surgery*. 2016;159:901–907.
28. Cherenfant J, Stocker SJ, Gage MK, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. *Surgery*. 2013;154: 785–791; discussion 791–793.
29. Postlewait LM, Ethun CG, Baptiste GG, et al. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. *J Surg Oncol*. 2016;114:440–445.
30. Parekh JR, Wang SC, Bergsland EK, et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: The UCSF experience with 149 patients. *Pancreas*. 2012;41: 840–844.
31. Hashim YM, Trinkaus KM, Linehan DC, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). *Ann Surg*. 2014;259:197–203.
32. Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: Impact on survival and implications for surgical resection. *J Gastrointest Surg*. 2015;19:152–160; discussion 160.
33. Hasegawa T, Yamao K, Hijioka S, et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. *Endoscopy*. 2014;46:32–38.
34. Weynand B, Borbath I, Bernard V, et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: High reproducibility and inter-observer agreement of the Ki-67 labelling index. *Cytopathology*. 2014;25:389–395.
35. Lowe K, Khithani A, Liu E, et al. Ki-67 labeling: A more sensitive indicator of malignant phenotype than mitotic count or tumor size? *J Surg Oncol*. 2012;106: 724–727.